v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock [Member]
Non-Controlling Interest [Member]
Common Stock
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive (Loss) Income [Member]
Accumulated Deficit [Member]
Beginning balance (in shares) at Dec. 31, 2024   103,460,716          
Beginning balance at Dec. 31, 2024   $ 789,853 $ (571)        
Beginning balance (in shares) at Dec. 31, 2024       32,691,628      
Beginning balance at Dec. 31, 2024 $ (434,519)     $ 33 $ 38,469 $ 118 $ (473,139)
Issuance of Series C convertible preferred stock (net of issuance costs of $28) (in shares)   1,856,539          
Issuance of Series C convertible preferred stock (net of issuance costs of $28)   $ 21,973          
Contributions from non-controlling interests     750        
Exercise of stock options (in shares)       146,702      
Exercise of stock options 483       483    
Stock-based compensation 4,744       4,744    
Vesting of restricted stock (in shares)       138,177      
Vesting of restricted stock 46       46    
Unrealized gain (loss) on marketable securities (71)         (71)  
Net loss attributable to Generate Biomedicines, Inc. stockholders (41,685)   (2,629)       (41,685)
Ending balance (in shares) at Mar. 31, 2025   105,317,255          
Ending balance at Mar. 31, 2025   $ 811,826 (2,450)        
Ending balance (in shares) at Mar. 31, 2025       32,976,507      
Ending Balance at Mar. 31, 2025 (471,002)     $ 33 43,742 47 (514,824)
Beginning balance (in shares) at Dec. 31, 2024   103,460,716          
Beginning balance at Dec. 31, 2024   $ 789,853 (571)        
Beginning balance (in shares) at Dec. 31, 2024       32,691,628      
Beginning balance at Dec. 31, 2024 (434,519)     $ 33 38,469 118 (473,139)
Unrealized gain (loss) on marketable securities (128)            
Net loss attributable to Generate Biomedicines, Inc. stockholders (94,114)            
Ending balance (in shares) at Jun. 30, 2025   105,317,255          
Ending balance at Jun. 30, 2025   $ 811,826 (4,763)        
Ending balance (in shares) at Jun. 30, 2025       33,022,208      
Ending Balance at Jun. 30, 2025 (517,847)     $ 33 49,383 (10) (567,253)
Beginning balance (in shares) at Mar. 31, 2025   105,317,255          
Beginning balance at Mar. 31, 2025   $ 811,826 (2,450)        
Beginning balance (in shares) at Mar. 31, 2025       32,976,507      
Beginning balance at Mar. 31, 2025 (471,002)     $ 33 43,742 47 (514,824)
Contributions from non-controlling interests     2,000        
Exercise of stock options (in shares)       45,701      
Exercise of stock options 154       154    
Stock-based compensation 5,487       5,487    
Unrealized gain (loss) on marketable securities (57)         (57)  
Net loss attributable to Generate Biomedicines, Inc. stockholders (52,429)   (4,313)       (52,429)
Ending balance (in shares) at Jun. 30, 2025   105,317,255          
Ending balance at Jun. 30, 2025   $ 811,826 (4,763)        
Ending balance (in shares) at Jun. 30, 2025       33,022,208      
Ending Balance at Jun. 30, 2025 $ (517,847)     $ 33 49,383 (10) (567,253)
Beginning balance (in shares) at Dec. 31, 2025 105,317,255 105,317,255          
Beginning balance at Dec. 31, 2025 $ 811,826 $ 811,826 (7,232)        
Beginning balance (in shares) at Dec. 31, 2025 33,116,957     33,116,957      
Beginning balance at Dec. 31, 2025 $ (615,965)     $ 33 60,189 106 (676,293)
Issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses (in shares)       25,000,000      
Issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses 369,289     $ 25 369,264    
Contributions from non-controlling interests     7,500        
Conversion of convertible preferred stock into common stock upon initial public offering (in shares)   (105,317,255)          
Conversion of convertible preferred stock into common stock upon initial public offering   $ (811,826)          
Conversion of convertible preferred stock into common stock upon initial public offering (in shares)       69,333,244      
Conversion of convertible preferred stock into common stock upon initial public offering 811,825     $ 69 811,756    
Reclassification of warrant liability to equity upon initial public offering 1,568       1,568    
Exercise of common stock warrants (in shares)       86,423      
Exercise of stock options (in shares)       655,860      
Exercise of stock options 3,217     $ 1 3,216    
Stock-based compensation 6,395       6,395    
Unrealized gain (loss) on marketable securities (82)         (82)  
Net loss attributable to Generate Biomedicines, Inc. stockholders (61,446)   (268)       (61,446)
Ending balance (in shares) at Mar. 31, 2026   0          
Ending balance at Mar. 31, 2026   $ 0 0        
Ending balance (in shares) at Mar. 31, 2026       128,192,484      
Ending Balance at Mar. 31, 2026 $ 514,801     $ 128 1,252,388 24 (737,739)
Beginning balance (in shares) at Dec. 31, 2025 105,317,255 105,317,255          
Beginning balance at Dec. 31, 2025 $ 811,826 $ 811,826 (7,232)        
Beginning balance (in shares) at Dec. 31, 2025 33,116,957     33,116,957      
Beginning balance at Dec. 31, 2025 $ (615,965)     $ 33 60,189 106 (676,293)
Unrealized gain (loss) on marketable securities (235)            
Net loss attributable to Generate Biomedicines, Inc. stockholders $ (128,701)            
Ending balance (in shares) at Jun. 30, 2026 0 0          
Ending balance at Jun. 30, 2026 $ 0   0        
Ending balance (in shares) at Jun. 30, 2026 128,269,428     128,269,428      
Ending Balance at Jun. 30, 2026 $ 456,045     $ 128 1,261,040 (129) (804,994)
Beginning balance (in shares) at Mar. 31, 2026   0          
Beginning balance at Mar. 31, 2026   $ 0 0        
Beginning balance (in shares) at Mar. 31, 2026       128,192,484      
Beginning balance at Mar. 31, 2026 514,801     $ 128 1,252,388 24 (737,739)
Exercise of stock options (in shares)       76,944      
Exercise of stock options 414       414    
Stock-based compensation 8,238       8,238    
Unrealized gain (loss) on marketable securities (153)         (153)  
Net loss attributable to Generate Biomedicines, Inc. stockholders $ (67,255)           (67,255)
Ending balance (in shares) at Jun. 30, 2026 0 0          
Ending balance at Jun. 30, 2026 $ 0   $ 0        
Ending balance (in shares) at Jun. 30, 2026 128,269,428     128,269,428      
Ending Balance at Jun. 30, 2026 $ 456,045     $ 128 $ 1,261,040 $ (129) $ (804,994)